Skye Bioscience Inc. was a sponsor at the Benzinga Cannabis Capital Conference on February 25-26, 2021. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. From the first research of tetrahydrocannabinol(THC) in 1964 by Raphael Mechoulam to the recent findings of the hundreds of cannabinoids that can alleviate symptoms of a plethora of illnesses and diseases, we now know cannabis is more than just weed and about getting high. Skye Bioscience Inc. (OTCQB:SKYE), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat diseases with significant unmet needs recently presented at the Benzinga Cannabis Capital Conference its approach to treating Glaucoma through unlocking the pharmaceutical value of THC.